Association for Multiple Endocrine Neoplasia Disorders

2015   Kate Lines, Oxford   Treatment with the epigenetic modifying compound JQ1+ can significantly reduce the proliferation of pancreatic neuroendocrine tumours in a mouse model of multiple endocrine neoplasia type 1 (MEN1)
2014   Umasuthan Srirangalingam, London   SDHB surveillance regime - a single UK institution experience
2013   Judit Dénes, London   Pituitary adenoma and phaeochromocytoma/paraganglioma - a novel syndrome with a heterogeneous genetic background
2012 spacer Candy Sze, London spacer Long term experience of 131I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?

Giampaolo Trivellin, London

  miR-107 inhibits the expression of aryl hydrocarbon receptor interacting protein (AIP) and is potentially involved in pituitary tumorigenesis
2010   Joint winners:    
    Zehra Ozfirat, London  

Geographical cluster of familial isolated pituitary adenoma kindreds with an identical AIP mutation

    Angela Taylor, Birmingham  

Development of urinary steroid profiling as a high-throughput screening tool for the detection of malignancy in patients with adrenal tumours